Latest publications

Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment. Boesjes CM, Van der Gang LF, Achten RE, Bakker DS, Van der Rijst LP, Dekkers CC et al. Expert Opin Biol Ther 2025 Dec 01

Targeting OX40: rocatinlimab-a novel therapy for atopic dermatitis. Atash K, Boesjes CM, De Bruin-Weller MS et al. Lancet 2025 Nov 25

Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real-world evidence. Van der Gang LF, De Bruin-Weller MS et al. J Eur Acad Dermatol Venereol 2025 Dec; 39(12):2026-2027

Reading the palms: Palmar hyperlinearity and type 2 biomarkers as early predictors of atopic dermatitis onset in infancy? Vroman F, De Graaf M et al. J Eur Acad Dermatol Venereol 2025 Dec; 39(12):2028-2029

Current treatment practices and efficacy in solar urticaria: insights from a patient survey. Kiefer L, Aulenbacher F, Terhorst-Molawi D, Giménez-Arnau AM, Gonçalo M, Fukunaga A et al. Front Immunol 2025; 16:1683524

Exploring the Disease Duration of Urticaria and Associated Determinants in Primary Care. Soegiharto R, Hengevelt BJ, Boekema-Bakker N, Groenewegen IAM, Knulst AC, Van den Reek JMPA et al. Clin Exp Allergy 2025 Oct 30

Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled Analysis. Paller AS, De Bruin-Weller M, Simpson EL, Ahn J, Chovatiya R, Deleuran M et al. Dermatitis 2025 Oct 14

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study. Augustin M, Tauber M, Sidbury R, Silverberg JI, Papp KA, Thaçi D et al. J Eur Acad Dermatol Venereol 2025 Oct 13

Real-Life Clinical Experience With SQ Grass, Tree, Ragweed, and House Dust Mite Sublingual Immunotherapy Tablets: A Review of Evidence From Non-Interventional Studies. Pfaar O, Janson C, Horn A, Knulst AC, Demoly P et al. Allergy 2025 Dec; 80(12):3290-3301

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions. De Bruin-Weller MS, Boesjes CM, Achten RA, Beck LA, Irvine AD, Vestergaard C et al. Allergy 2025 Sep 24

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage). Warren RB, De Bruin-Weller M, Tsianakas A, Khemis A, Szepietowski JC, Hong HC et al. Br J Dermatol 2025 Oct 17; 193(5):876-888

Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry. Paller AS, Marcoux D, Ramien M, Baselga E, Carvalho VO, Ardusso LRF et al. Am J Clin Dermatol 2025 Nov; 26(6):1031-1043

Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A et al. Am J Clin Dermatol 2025 Nov; 26(6):1003-1016

Response to Bissonnette et al "Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)". Clabbers J, Boesjes C, Van Geel M, De Bruin-Weller M, Gostynski A et al. J Am Acad Dermatol 2025 Aug 29

Management of Chronic Spontaneous Urticaria Made Practical: What Every Clinician Should Know. Kocatürk E, Chu DK, Türk M, Röckmann H, Van Doorn M, Nochaiwong S et al. J Allergy Clin Immunol Pract 2025 Sep; 13(9):2252-2269